Pharmathen, a leading European company in complex drug production and formulation development, with a strong sense of responsibility and responding to the urgent needs arising from the floods Daniel and Elias in Thessaly, has donated 250 beds and mattresses to 150 families in the Municipality of Kileler, to alleviate the suffering of those affected. The delivery of the donated materials took place on Monday, December 18, to representatives of the Municipality, with the aim of distributing them to the villages that have suffered the most significant damage to their infrastructure, including Sotirio, Armenio, Megalo Monastery, Kileler, Niki, and Kalo Nero.
This specific donation is a continuation of the initial aid provided by Pharmathen to the affected individuals, which involved ready-to-eat, cooked meals in a long-lasting preserved form, along with clothing, waterproof suits, masks, and disinfectants. The purpose is to actively contribute and assist in addressing the immediate needs that arose for the residents after the disaster.
Mr. Dimitris Kadis, CEO of Pharmathen, stated: "At Pharmathen, we believe in the power of solidarity, and we actively support our fellow citizens. Following the devastating floods in Thessaly, we stand by the residents of the Municipality of Kileler and want to contribute to the reconstruction of these communities. Through this donation, we express our deep sympathy and our intention to stand by those who have been affected."
Mr. Thanasis Nasiakopoulos, Mayor of the Municipality of Kileler, stated: "We greatly thank Pharmathen, that, from the beginning, responded promptly and sensitively to the needs that arose in our municipality, effectively supporting the residents of our villages who suffered significant damage at their properties. In this challenging period, such actions are particularly important for us to be able to fulfill our duties. Through this donation, we will address one of the basic daily needs for 150 families in our municipality.".
Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies. With best-in-class research & development capabilities, Pharmathen is currently working on one of the most extensive and advanced pipelines in the industry consisting of more than 40 products, with a focus on long-acting injectables, sustained release and ophthalmic formulations produced in its FDA and EU approved facilities. Pharmathen’s highly diversified product portfolio of more than 90 commercialized products is sold to 250 customers and accessed by patients in more than 90 countries worldwide.